JAMP-FINASTERIDE TABLET

Kraj: Kanada

Język: angielski

Źródło: Health Canada

Kup teraz

Składnik aktywny:

FINASTERIDE

Dostępny od:

JAMP PHARMA CORPORATION

Kod ATC:

G04CB01

INN (International Nazwa):

FINASTERIDE

Dawkowanie:

5MG

Forma farmaceutyczna:

TABLET

Skład:

FINASTERIDE 5MG

Droga podania:

ORAL

Sztuk w opakowaniu:

30

Typ recepty:

Prescription

Dziedzina terapeutyczna:

5 ALFA REDUCTASE INHIBITORS

Podsumowanie produktu:

Active ingredient group (AIG) number: 0124110001; AHFS:

Status autoryzacji:

APPROVED

Data autoryzacji:

2014-10-10

Charakterystyka produktu

                                _JAMP-Finasteride_
_(finasteride) _
_ _
_ _
_ _
_Page 1 of 31_
PRODUCT MONOGRAPH
PR
JAMP-FINASTERIDE
Finasteride Tablets, USP
Film-coated Tablets 5 mg
Type II 5α-reductase inhibitor
JAMP PHARMA CORPORATION
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
DATE OF REVISION:
April 5, 2023 SUBMISSION CONTROL NO.: 268915
_JAMP-Finasteride_
_(finasteride) _
_ _
_ _
_ _
_Page 2 of 31_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
..................................................................................
4
ADVERSE REACTIONS
...................................................................................................
6
DRUG
INTERACTIONS
.....................................................................................................
9
DOSAGE AND ADMINISTRATION
..............................................................................
10
OVERDOSAGE
................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 12
STORAGE AND STABILITY
..........................................................................................
13
SPECIAL HANDLING INSTRUCTIONS
.......................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 13
PART II: SCIENTIFIC INFORMATION
................................................................................
14
PHARMACEUTICAL INFORMATION
..........................................................................
                                
                                Przeczytaj cały dokument
                                
                            

Dokumenty w innych językach

Charakterystyka produktu Charakterystyka produktu francuski 05-04-2023

Wyszukaj powiadomienia związane z tym produktem